CG Oncology Stock Soars After Bladder Cancer Drug Cuts Recurrence Risk by 68% in Pivotal Phase 3 Trial Win
CG Oncology Inc. shares rose 11.47% after its bladder cancer drug, cretostimogene, showed a 68% reduction in recurrence risk in a Phase 3 trial. The stock reached $82.93, with high trading volume. The trial met its primary goal, and the therapy was well-tolerated. The company's market value is about $7.4 billion. CG Oncology plans to seek U.S. approval for the drug.
How this was made

The 30-second read
Why it matters
A pivotal Phase 3 primary endpoint win with a large recurrence-risk reduction strengthens the approval case and may broaden the eventual U.S. label, supporting continued momentum in the near term while increasing sensitivity to future data granularity and regulatory timing.
Market read
Traders can act on a fresh, pivotal clinical catalyst that changes approval odds and near-term expectations for regulatory filing and subsequent data releases.
What to watch
The article notes a pullback from premarket highs, suggesting profit-taking; traders should monitor the exact regulatory filing scope, upcoming meeting details, and any additional endpoints beyond recurrence risk.
Background
The company’s cretostimogene grenadenorepvec is an oncolytic immunotherapy delivered directly into the bladder, studied in NMIBC after tumor removal and also in BCG-unresponsive disease.
Ticker impact
CG Oncology shares surged after Phase 3 PIVOT-006 met its primary endpoint, cutting bladder cancer recurrence risk by 68% (HR 0.32, p<0.0001).
Likely upward bias as the market reprices approval odds and future filing scope, with volatility around regulatory/timeline details.
The article reports a primary endpoint win with hazard ratio and p-value, plus a stated path toward broader U.S. filing; these are direct, decision-relevant catalysts for biotech valuation.
Market effects
Reinforces investor appetite for bladder cancer immunotherapy and oncolytic platforms, potentially lifting sentiment for adjacent clinical-stage oncology names.
Primarily impacts U.S. Nasdaq biotech tape via a single-name repricing; limited broader regional spillover expected beyond biotech complex.
Could influence global oncology trial expectations for NMIBC recurrence endpoints, but the immediate tradable effect is concentrated in the issuer’s shares.
Counterpoint
Even with a strong hazard ratio, approval is not guaranteed; investors may fade the move if subsequent analyses, subgroup consistency, or safety signals do not hold up at regulatory review.
Key entities
- companyCG Oncology Inc.
Nasdaq-listed biotech whose Phase 3 PIVOT-006 trial results drove a sharp share move.
- drugcretostimogene grenadenorepvec
Oncolytic immunotherapy tested in the Phase 3 trial for intermediate-risk NMIBC recurrence reduction.
- clinical_trialPIVOT-006 Phase 3 trial
367-patient study in intermediate-risk NMIBC after complete tumor removal; met primary endpoint with HR 0.32.



